Latest Articles

Publication Date
Risk factors for infection after hysterectomy for benign disease.

Our objective was to identify risk factors for infections following hysterectomy for benign disease.

Published: Oct. 5, 2026, midnight
Simvastatin and Primaquine Identified as Potential Endometriosis Therapeutics via a Novel Epithelial-Stromal Assembloid Drug Screening Assay.

Endometriosis is an estrogen-driven, inflammatory disorder affecting ~10% of menstruators, causing severe pain. Current treatments that reduce estrogen or inflammation have inconsistent efficacy and poor tolerability. Therapies identified via drug-repositioning …

Published: Sept. 27, 2026, midnight
Use of Ibuprofen Before and in Early Pregnancy Among Women With and Without Chronic Medical Diseases. A Cross-Sectional Study.

While having a chronic medical disease (CMD) increases use of analgesics and anti-inflammatory drugs, sufficient knowledge regarding patterns of use during pregnancy is lacking. We aimed to describe ibuprofen use …

Published: Sept. 24, 2026, midnight
Ovarian fibrosis as a common mechanism of infertility.

Female fertility has long been explained through observation of the ovarian follicle: the number of residing follicles and the quality of the oocyte. This review argues that the tissue surrounding …

Published: Sept. 24, 2026, midnight
Single-Cell RNA Sequencing Reveals Immune Dysregulation and Candidate Drug Targets in Endometriosis.

Endometriosis is a chronic inflammatory disorder affecting 5-10% of women of reproductive age and is associated with chronic pain and infertility. While research has mainly focused on local lesions, systemic …

Published: Sept. 19, 2026, midnight
β-Glucuronidase at the gut-liver interface: Structural selectivity, enterohepatic reactivation, and the pharmacomicrobiomic case for precision inhibition.

β-Glucuronidase (β-G, EC 3.2.1.31) reverses phase II glucuronidation, and microbial β-G at the gut-liver interface reactivates biliary and circulating conjugates, closing enterohepatic loops for drugs, estrogens, bile acids, and bilirubin. …

Published: Sept. 9, 2026, midnight
Ectopic Endometrium-Targeted M1 Macrophage-Derived Nanovesicles for Treatment of Endometriosis.

Endometriosis (EMs) is a common gynecological disorder in women of reproductive age, often presenting with pelvic pain and infertility. Its progression is closely linked to estrogen levels. While hormonal therapies …

Published: Sept. 8, 2026, midnight
Targeting Cathepsin Z suppresses endometriosis via the AMPK/mTOR-mediated autophagy and apoptosis axis.

The key biomarkers, therapeutic targets, and pathological mechanisms of endometriosis are urgently needed to be elucidated. The role of CTSZ in EM needs to be clarified, and the potential regulatory …

Published: Sept. 1, 2026, midnight
Exploring predictors of analgesic response in adult women regularly using NSAIDs: insights from a machine learning approach.

Non-steroidal anti-inflammatory drugs (NSAIDs) are considered a first-line treatment for dysmenorrhea (menstrual pain). However, as much as 20% of women fail to achieve sufficient pain relief from NSAIDs, although factors …

Published: July 29, 2026, midnight
Integrating single-cell and bulk transcriptomic perturbation resources reveals complementary therapeutic spaces for drug repurposing.

Transcriptome-based drug repurposing can accelerate therapeutic discovery, but is limited by fragmented resources, inconsistent quality control, and reliance on single perturbation databases. We developed CDRPipe ( C omputational D rug …

Published: July 22, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!